Pharmacogenomic discovery approaches: Will the real genes please stand up?

Journal of Clinical Oncology

Volumn 23, Issue 29, 2005, Pages 7342-7349

  Walgren, Richard A ^a   Meucci, Melissa A ^a   McLeod, Howard L ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR;

COLORECTAL CANCER; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; INHERITANCE; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; GENETICS; GENOME; METHODOLOGY; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

GENOME, HUMAN; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33644691227     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.0825     Document Type: Review

References (52)

1. Evans WE, Belling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491, 1999
2. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144-146, 2001
3. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
4. Vesell ES, Page JG: Genetic control of drug levels in man: Phenylbutazone. Science 159:1479-1480, 1968
5. Vesell ES, Page JG: Genetic control of drug levels in man: Antipyrine. Science 161: 72-73, 1968
6. Vesell ES, Page JG: Genetic control of dicumarol levels in man. J Clin Invest 47:2657-2663, 1968
7. Kalow W: Pharmacogenetics: Heredity and the Response to Drugs. Philadelphia, PA and London, United Kingdom, W.B. Saunders Co, 1962
8. Evans WE, McLeod HL: Pharmacogenomics: Drug disposition, drug targets, and side effects. N Engl J Med 348:538-549, 2003
9. Watters JW, McLeod HL: Cancer pharmacogenomics: Current and future applications. Biochim Biophys Acta 1603:99-111, 2003
10. Timbrell JA, Harland SJ, Facchini V: Polymorphic acetylation of hydralazine. Clin Pharmacol Ther 28:350-355, 1980
11. Reidenberg MM, Drayer DE, Levy M, et al: Polymorphic acetylation procainamide in man. Clin Pharmacol Ther 17:722-730, 1975
12. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662, 1980
13. Bertilsson L, Lou YQ, Du YL, et al: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397, 1992
14. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
15. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
16. Villafranca E, Okruzhnov Y, Dominguez MA, et al: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19: 1779-1786, 2001
17. Das PM, Singal R: DNA methylation and cancer. J Clin Oncol 22:4632-4642, 2004
18. Petricoin EF III, Bichsel VE, Calvert VS, et al: Mapping molecular networks using proteomics: A vision for patient-tailored combination therapy. J Clin Oncol 23:3614-3621, 2005
19. Weir B, Zhao X, Meyerson M: Somatic alterations in the human cancer genome. Cancer Cell 6:433-438, 2004
20. van't Veer LJ, Paik S, Hayes DF: Gene expression profiling of breast cancer: A new tumor marker. J Clin Oncol 23:1631-1635, 2005
21. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
22. Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854, 1998
23. Iyer L, Hall D, Das S, et al: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582, 1999
24. Fisher MB, Vandenbranden M, Findlay K, et al: Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: Relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727-739, 2000
25. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002
26. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000
27. Innocenti F, Undevia SD, lyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
28. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 23:2556-2568, 2005
29. Janne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23:3227-3234, 2005
30. Dausset J, Cann H, Cohen D, et al: Centre d'etude du polymorphisme humain (CEPH): Collaborative genetic mapping of the human genome. Genomics 6:575-577, 1990
31. Schork NJ, Gardner JP, Zhang L, et al: Genomic association/linkage of sodium lithium countertransport in CEPH pedigrees. Hyperten-sion 40:619-628, 2002
32. Cheung VG, Conlin LK, Weber TM, et al: Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 33:422-425, 2003
33. Jen KY, Cheung VG: Transcriptional response of lymphoblastoid cells to ionizing radiation. Genome Res 13:2092-2100, 2003
34. Dolan ME, Newbold KG, Nagasubramanian R, et al: Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 64:4353-4356, 2004
35. Watters JW, Kraja A, Meucci MA, et al: Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 101:11809-11814, 2004
36. Ober C: Susceptibility genes in asthma and allergy. Curr Allergy Asthma Rep 1:174-179, 2001
37. Wu XX, Kakehi Y, Mizutani Y, et al: Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 19:19-24, 2001
38. Kolfschoten GM, Hulscher TM, Duyndam MC, et al: Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 63:733-743, 2002
39. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer: International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17: 1356-63, 1999
40. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349-1355, 1999
41. Wang Y, Jatkoe T, Zhang Y, et al: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22:1564-1571, 2004
42. van't Veer LJ, Dai H, van de Vijver MJ, et al: Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5:57-58, 2003
43. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
44. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
45. Lugthart S, Cheok MH, den Boer ML, et al: Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7:375-386, 2005
46. Holleman A, Cheok MH, den Boer ML, et al: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542, 2004
47. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
48. Simon R, Maitournam A: Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10:6759-6763, 2004
49. Silver LM: Mouse Genetics, Concepts and Applications. Oxford, United Kingdom, Oxford University Press, 1995
50. Haston CK, Wang M, Dejournett RE, et al: Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet 11:1855-1863, 2002
51. Beck JA, Lloyd S, Hafezparast M, et al: Genealogies of mouse inbred strains. Nat Genet 24:23-25, 2000
52. Wade CM, Kulbokas EJ III, Kirby AW, et al: The mosaic structure of variation in the laboratory mouse genome. Nature 420:574-578, 2002